The antibody–drug conjugate trastuzumab deruxtecan (T-DXd) (Enhertu, Daiichi Sankyo/AstraZeneca) is emerging as a treatment option for any late-stage tumor, regardless of location, that expresses HER2 if options for disease control are diminishing, according to data from the phase 2 DESTINY-PanTumor02 trial. The findings were reported at the 2023 annual meeting of the American Society of Clinical Oncology (abstract LBA3000).
Supporting the mechanism of benefit, a greater level of HER2